Propel Bio Management, LLC Avidity Biosciences, Inc. Transaction History
Propel Bio Management, LLC
- $172 Billion
- Q1 2024
A detailed history of Propel Bio Management, LLC transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Propel Bio Management, LLC holds 178,500 shares of RNA stock, worth $8.2 Million. This represents 2.65% of its overall portfolio holdings.
Number of Shares
178,500
Previous 178,500
-0.0%
Holding current value
$8.2 Million
Previous $1.62 Billion
181.99%
% of portfolio
2.65%
Previous 1.34%
Shares
1 transactions
Others Institutions Holding RNA
# of Institutions
169Shares Held
71.6MCall Options Held
182KPut Options Held
55K-
Rtw Investments, LP New York, NY7.97MShares$366 Million3.26% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD7.43MShares$341 Million0.02% of portfolio
-
Black Rock Inc. New York, NY6.17MShares$283 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.83MShares$268 Million1.79% of portfolio
-
Cowen And Company, LLC5.63MShares$259 Million4.83% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $2.4B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...